Moreover, in vivo and in vitro experiments showed that the PBRM1 mutation did not affect the proliferation of CRC cells; however, it significantly promoted their sensitivity to PD1 antibody treatment. This evidence concerns the gene PDCD1 and colorectal carcinoma.